OMB APPROVAL

OMB Number: Expires:

Estimated average burden hours per response

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number <u>1-32001</u>
Lorus Therapeutics Inc.-NYSE Alternext

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

2 Meridian Road, Toronto, Ontario, Canada M9W 4Z7 416-798-1200 (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Shares

(Description of class of securities)

	Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
]	17 CFR 240.12d2-2(a)(1)
]	17 CFR 240.12d2-2(a)(2)
]	17 CFR 240.12d2-2(a)(3)
]	17 CFR 240.12d2-2(a)(4)
]	Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.
ζ.	Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
equ	Pursuant to the requirements of the Securities Exchange Act of 1934, Lorus Therapeutics Inc.certifies that it has reasonable grounds to believe that it meets all of the irements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

			Director of Finance, Acting
October 21, 2008	Ву	/s/ Elizabeth Williams	Chief Financial Officer
Date		Elizabeth Williams	Title

SEC1654(03-06)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.